Tela bio, inc. TELA.US Overview
TELA AI Analysis & Strategy
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
TELA Current Performance
-4.15%
Tela bio, inc.
-0.14%
Avg of Sector
-0.00%
S&P500
TELA Key Information
TELA Financial Forecast
Unit : USD
TELA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.25 | -8.7% | 19% | 18.52M | 11.5% | 6.7% | -52.2% |
| 2024Q3 | -0.23 | 56.6% | -4.2% | 17.65M | 3.8% | -16.1% | -54.7% |
| 2024Q2 | -0.42 | 6.7% | 13.5% | 18.96M | 25.9% | -18.2% | -78.3% |
| 2024Q1 | -0.51 | -10.9% | 13.3% | 16.09M | 11% | -12.8% | -34.1% |
| 2023Q4 | -0.23 | 63.5% | -52.1% | 16.6M | 39.4% | 1.7% | -75.8% |
TELA Profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.